0RN3 Stock Chart & Stats
€35.20
€0.00(0.00%)
At close: 4:00 PM EDT
€35.20
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€35.20 - €35.20
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€52.66B
Enterprise Value€12.75M
Total Cash (Recent Filing)€527.58B
Total Debt (Recent Filing)€4.94T
Price to Earnings (P/E)52.3
BetaN/A
Next Earnings
Oct 29, 2026EPS Estimate
0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)114.22
Shares Outstanding1,602,141,400
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)1.15
Price to Sales (P/S)1.98
P/FCF Ratio11.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€38.84Price Target Upside10.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.69
Revenue Forecast (FY)€26.19B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSubstantial operating and free cash flow gives Takeda internal funding for research, launches, debt management and shareholder returns. This cash-generative model can support strategic investment without relying entirely on external financing, strengthening resilience over the next several quarters.
Pipeline And Launch MomentumPriority regulatory review for zasocitinib adds a potentially important late-stage growth driver to Takeda's branded portfolio. Combined with demonstrated Phase 3 efficacy, the program increases the opportunity to offset mature-product declines and broaden future revenue sources.
Improving Balance-Sheet LeverageDeclining debt-to-equity and a growing equity base improve financial flexibility for a global biopharmaceutical company. Better leverage creates more capacity to fund pipeline development and commercial launches while reducing balance-sheet pressure across the medium term.
Bears Say
Constant-Currency Revenue PressureUnderlying revenue contraction at constant exchange rates indicates that reported growth is not fully reflecting organic business expansion. Continued mature-product pressure and launch investment could constrain near-term earnings until newer products achieve broader commercial scale.
Thin And Volatile Bottom-Line ReturnsLow and volatile net profitability means strong gross and operating margins are not consistently converting into shareholder returns. This leaves earnings more exposed to below-the-line pressures and limits the capital efficiency generated by Takeda's sizeable asset base.
Mature-Product Erosion And Access ConstraintsLoss of exclusivity creates a durable headwind for established products, while delayed Chinese public reimbursement may slow adoption of a newly approved therapy. These factors can reduce the speed at which pipeline launches replace declining legacy revenue.
0RN3 FAQ
What was Takeda Pharmaceutical Co Ltd’s price range in the past 12 months?
Takeda Pharmaceutical Co Ltd lowest share price was €35.20 and its highest was €35.20 in the past 12 months.
What is Takeda Pharmaceutical Co Ltd’s market cap?
Takeda Pharmaceutical Co Ltd’s market cap is €52.66B.
When is Takeda Pharmaceutical Co Ltd’s upcoming earnings report date?
Takeda Pharmaceutical Co Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 40 days.
How were Takeda Pharmaceutical Co Ltd’s earnings last quarter?
Takeda Pharmaceutical Co Ltd released its earnings results on Jul 30, 2026. The company reported €0.398 earnings per share for the quarter, beating the consensus estimate of €0.302 by €0.096.
Is Takeda Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Takeda Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Takeda Pharmaceutical Co Ltd pay dividends?
Takeda Pharmaceutical Co Ltd does not currently pay dividends.
What is Takeda Pharmaceutical Co Ltd’s EPS estimate?
Takeda Pharmaceutical Co Ltd’s EPS estimate is 0.26.
How many shares outstanding does Takeda Pharmaceutical Co Ltd have?
Takeda Pharmaceutical Co Ltd has 1,602,141,400 shares outstanding.
What happened to Takeda Pharmaceutical Co Ltd’s price movement after its last earnings report?
Takeda Pharmaceutical Co Ltd reported an EPS of €0.398 in its last earnings report, beating expectations of €0.302. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Takeda Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in GB:0RN3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
0RN3 Company Deck
0RN3 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of modest near-term CER declines and cash-flow timing effects against substantial positive developments: strong FX-driven reported results, confirmation of transformation-led funding for launches, multiple imminent regulatory and commercial milestones (ORZEYFUL approval in China; rusfertide priority review; superior zasocitinib data), and a robust late-stage pipeline with several programs moving to pivotal stages. While Q1 contained some one-time impacts, transitional investment effects and product-specific headwinds, the combination of pipeline momentum, launch readiness and a maintained full-year financial outlook suggests the company is positioned to convert R&D progress into revenue growth later in the year.View all GB:0RN3 earnings summaries0RN3 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€38.84
▲(10.33% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Sumitomo Dainippon Pharma Co
―
Eisai Co
―
―
Shionogi & Co
―
Nippon Shinyaku Co., Ltd.
―











